Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

NexImmune, Inc. (NEXI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.5546-0.0034 (-0.61%)
At close: 04:00PM EDT
0.5125 -0.04 (-7.59%)
After hours: 07:59PM EDT
Advertisement

NexImmune, Inc.

9119 Gaither Road
Gaithersburg, MD 20877
United States
301 825 9810
https://www.neximmune.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees74

Key Executives

NameTitlePayExercisedYear Born
Ms. Kristi Jones R.Ph.CEO, Pres & Director520.87kN/A1963
Mr. John Trainer M.B.A.Chief Financial Officer514.67kN/A1974
Dr. Jerome Bernard Zeldis M.D., Ph.D.Exec. VP of R&D405.79kN/A1950
Dr. Robert Douglas Knight M.D.Chief Medical Officer454.77kN/A1951
Dr. Mathias Oelke Ph.D.Chief Scientific OfficerN/AN/A1968
Dr. Jeffrey S. Weber M.D., Ph.D.Chief Scientific Advisor, Co-Chairman of Scientific Advisory Board and Member of AI & ID SABN/AN/AN/A
Mr. Karen HaslbeckHead of HRN/AN/AN/A
Dr. Daniel P. BednarikSr. VP of Molecular Engineering & Protein DesignN/AN/AN/A
Mr. Chad RubinSr. VP of Corp. AffairsN/AN/AN/A
Dr. Jack A. Ragheb M.D., Ph.D.Sr. VP of Translational ScienceN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

NexImmune, Inc.’s ISS Governance QualityScore as of July 1, 2022 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement